Skip to main content
Home

Breadcrumb

  1. Home
  2. News
  3. Search results
Displaying results 1 - 25 of 643 Clear search
Zyme Communications
logo
Healthcare and Life Science 01 Oct 2026

CN Bio announces expert speaker line-up and scientific program for inaugural Organ-on-a-chip e-Symposium

Four sessions across twodays focusing on key drug discovery and development application areas of organ-on-a-chip technologies Expert-led presentations and panel discussions featuring leaders across research, regulatory and industry, including Novo
Zyme Communications
David Venables, CEO of Laverock Therapeutics
Healthcare and Life Science 30 Sep 2026

Laverock Therapeutics announces in vivo programmes in oncology and genetic medicine

Laverock's programmable gene control platform unlocks in vivo therapeutics with enhanced efficacy and safety

Zyme Communications
Dr Ian Jepson, Non-Executive Director, Cytotrait	Dr Tim Brears, Executive Chair, Cytotrait
Healthcare and Life Science 29 Sep 2026

Cytotrait appoints Dr Ian Jepson as Non-Executive Director

Accomplished international R&D executive, previously Syngenta, specialising in biotech trait development and genome editing technologiesFollows £3M seed round in 20261 to expand capabilities of the Company’s core MOSS platform and establish trait enhancem
Zyme Communications
Eppendorf SpinPro 8 R
Healthcare and Life Science 23 Sep 2026

Eppendorf introduces the new SpinPro® 8 R high-speed centrifuge

Eppendorf, a leading international life science company that develops, manufactures, and distributes instruments, consumables, and services for use in laboratories around the world, today announced the expansion of its centrifuge portfolio with the launch of the new SpinPro 8 R, a refrigerated, f

Zyme Communications
Novai logo
Healthcare and Life Science 23 Sep 2026

Novai publishes study supporting use of DARC imaging technology to identify patients at risk of central vision loss from macular atrophy

Novai.

Zyme Communications
logo
Healthcare and Life Science 17 Sep 2026

Big Picture Bio founded to identify, design and optimise promising cancer combination therapies

New company founded by Deep Science Ventures veterans closes £1.5M (~$2M USD) pre-seed round and secures £700K (~$950K USD) Innovate UK fundingFounding team and advisors bring expertise from Deep Science Ventures, AstraZeneca, Exscientia and PhoreMostI
Zyme Communications
Flip™ product platform
Healthcare and Life Science 15 Sep 2026

Fuse Diagnostics raises £1 million to scale rapid point-of-need molecular testing platform

Financing will accelerate commercialisation of Fuse Diagnostics’ proprietary Flip platform, expanding its portfolio of rapid, laboratory-quality molecular diagnostics for high-value industrial and life science applicationsInvestment led by The FSE Group alongside existi
Zyme Communications
Nicolas Koebel, Chief Executive Officer of EpilepsyGTx	Jimmy Vanhove, Chief Executive Officer of Viralgen
Healthcare and Life Science 09 Sep 2026

EpilepsyGTx and Viralgen collaborate to advance AAV gene therapy programme for epilepsy ahead of first-in-human trial

Collaboration with AAV-specialist CDMO will support scalable production of EPY201 for focal refractory epilepsy affecting 10 million people

Zyme Communications
Eppendorf Centrifuge 5811 R
Healthcare and Life Science 08 Sep 2026

Eppendorf launches new refrigerated Centrifuge 5811 R

Hamburg, Germany, 8 September, 2026 – Eppendorf, a leading international life science company that develops, manufactures, and distributes instruments, consumables, and services for use in laboratories around the world, today announced the launch of the Centrifuge 5811

Zyme Communications
Dr Julian Gough, CEO and Founder, OutSee	Dan Bolser, Principal Bioinformatician, OutSee
Healthcare and Life Science 08 Sep 2026

OutSee awarded Innovate UK grant for agentic AI pilot study to enhance drug target validation

Pilot study to develop prototype agentic AI sub-system for initial validation screening of targets identified using AI predictive genomics platform, NomalyFunding provided jointly by Innovate UK and Empirical Ventures through Innovate UK Growth Catalyst – Investor Partn
Zyme Communications
bio-rad.com
Healthcare and Life Science 01 Sep 2026

Bio-Rad expands Foresight Pro Prepacked Chromatography Columns with Nuvia Ion Exchange and Mixed-Mode Resins for Biomanufacturing

Extended Range of Process-Scale Columns Prepacked with CEX, AEX, CEX-HIC, and AEX-HIC Chromatography Resins Provides an Effective Solution for Purification of Biomolecules in Downstream Processing

Zyme Communications
Carterra logo
Healthcare and Life Science 25 Aug 2026

Carterra Enables Anthropic's Autonomous AI Protein Design Study via its HT-SPR Binding Platforms

Carterra®, a leading provider of high-throughput surface plasmon resonance (HT-SPR) platforms for antibody and small molecule drug discovery, today highlighted the role of Carterra HT-SPR in one of the largest published wet-lab validations of AI-designed proteins to date.

Zyme Communications
Image: Dual binding Fab functioning as a conditional trans-activation logic gate for IL-12
Healthcare and Life Science 20 Aug 2026

FairJourney Bio delivers antibody engineering for novel tumor-conditional IL-12 therapeutic approach that unlocks the potential of localized cytokine activation

Study in mAbs describes the first reported demonstration of a reversible trans-activation logic gate for tumor-conditional cytokine delivery FJBio engineered dual-specificity Fabs to meet model-defined affinity window through an end-to-end campaign across Porto and
Zyme Communications
The Qureight team at the new London office
Healthcare and Life Science 19 Aug 2026

Qureight expands with addition of second site, to accommodate rapid growth and ongoing development of chest Foundation Model

Investment in new premises in London reflects significant milestone in Company’s growth, following $20 million Series B financingSupports rapid scale-up and development of foundational AI imaging model, to improve clinical trial design across broader range of chest dise
Zyme Communications
Dr Jack Kennefick,  CEO and Co-Founder,  Tagomics
Healthcare and Life Science 17 Aug 2026

Tagomics introduces LiquiPath, a first-in-class cfDNA-based blood test for multi-organ drug safety monitoring

Non-invasive cell-free DNA liquid biopsy platform for multi-organ monitoring of drug-safety across preclinical and clinical settings Early access programme now open for drug developers to shape future platform capabilities and applicationsNew bran
Zyme Communications
https://www.syngensys.com/
Healthcare and Life Science 13 Aug 2026

SynGenSys introduces expanded CHO.SET synthetic promoter library for enhanced biomanufacturing

·       CHO.SET® 2.0 library of synthetic promoters provide tuneable expression of transgenes whilst maximising CHO cell productivity

Zyme Communications
cn-bio.com
Healthcare and Life Science 12 Aug 2026

CN Bio awarded Innovate UK grant to reduce animal use in pharmacokinetic studies

Grant funding delivered in partnership with the NC3Rs, in support of UK Government roadmap to reduce animal testing by 2030 Project to develop standardized workflow to more accurately predict drug behaviors, reduce animal testing and streamline development of safer
Zyme Communications
www.callali.ly/
Healthcare and Life Science 11 Aug 2026

Calla Lily Clinical Care selected to join Wellcome Leap’s $50M Focused Antibiotics Programme

Callavid intravaginal drug delivery platform selected to advance targeted UTI treatment as part of new programme addressing antibiotic-driven antimicrobial resistance

Zyme Communications
Terry Pizzie, CEO, Broken String Biosciences
Healthcare and Life Science 10 Aug 2026

Broken String Biosciences launches BaseMap ABE to enable genome-wide off-target characterization in base editing therapeutic development

•        Extension of the INDUCE-seq platform to support adenine base editing (ABE) workflows•        Researchers invited to gain early access to platform and support ongoing product development

Zyme Communications
DNA Script
Healthcare and Life Science 04 Aug 2026

DNA Script and leading healthcare solutions provider awarded up to $26M by ARPA-H to advance cell-free DNA bioproduction

FLASH program, in collaboration with GE HealthCare, to support development of faster, distributed DNA manufacturing for next-generation therapies

Zyme Communications
Muhunthan Thillai, Co-founder and CEO, Qureight and Inga Deakin, Partner, Molten Ventures
Healthcare and Life Science 29 Jul 2026

Qureight closes $20 million Series B financing

Round led by Molten Ventures alongside existing investors Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind, and Ascension Investment will support Qureight’s next-generation AI-powered quantitative imaging platform to further accelerate clinica
Zyme Communications
Medra AI is a pioneer in Lab-in-the-Loop deployment for drug discovery where Carterra’s LSA-XT (shown here) is a workhorse generating more antibody binding data than any other platform
Healthcare and Life Science 27 Jul 2026

Leerink Partners Report Names Carterra a Core Enabler of the $7B "Lab-in-the-Loop" Antibody Discovery Market

New research on AI-driven biologics discovery identifies Carterra's high-throughput SPR platforms as central to the Lab-in-the-Loop (LitL) workflow reshaping drug discovery, with Twist Bioscience and Adaptyv Bio pointing to surging demand for Carterra technology

Zyme Communications
https://www.syngensys.com/
Healthcare and Life Science, Science and Engineering 22 Jul 2026

SynGenSys makes key appointments to strengthen senior commercial and scientific teams

· Heads of Commercial, CHO Expression Technologies, Cell and Gene Therapy Expression Technologies, and Bioinformatics and Data Science appointed to support commercial scale-up

Zyme Communications
Dr Teresa Nunes, Chief Medical Officer of EpilepsyGTx
Healthcare and Life Science, Science and Engineering 22 Jul 2026

EpilepsyGTx appoints Dr Teresa Nunes as Chief Medical Officer

Appointment of senior clinical leader will support progression of lead candidate EPY201 through the clinic 

Zyme Communications
The Antibody Series
Healthcare and Life Science 21 Jul 2026

FairJourney Bio announces scientific program and leadership for The Antibody Series 2026

Annual event brings together international experts in antibody discovery and development, taking place September 16–18, 2026, in Évora, Portugal

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • …
  • Next page ›
  • Last page »
Receive our newsletter

Cambridge Network Limited is a company registered in England under company No. 3400152

The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT

Email: [email protected], Tel: 01223 746801

© 2026 Cambridge Network. All Rights Reserved.

Website by KISS